Patents by Inventor Philippe Wagner

Philippe Wagner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220025944
    Abstract: A brake system for an electric wheel drive unit has a housing that can be attached securely to the vehicle frame. The housing has a flange region and a shaft-like wheel carrier region secured to the flange region. A first brake component is connected to the housing and includes a first support part attached directly on a radial outer side of the wheel carrier region and a first brake disc element rotationally fixed to the first support part. A second brake component is rotatably mounted relative to the housing and has a second support part and a second brake disc element rotationally fixed to the second support part. A hydraulic actuation device is provided with one or more pressure pistons arranged. A sliding element is provided for moveably coupling the pressure pistons with one of the brake disc elements.
    Type: Application
    Filed: December 6, 2019
    Publication date: January 27, 2022
    Applicant: Schaeffler Technologies AG & Co. KG
    Inventors: Doris Maria Wimmer, Simon Ortmann, Philippe Wagner
  • Patent number: 11214608
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: January 4, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Heiko Schuster, Janet Peper, Kevin Roehle, Philipp Wagner, Hans-Georg Rammensee
  • Publication number: 20210363221
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: July 9, 2021
    Publication date: November 25, 2021
    Inventors: Heiko SCHUSTER, Janet PEPER, Kevin ROEHLE, Philipp WAGNER, Hans-Georg RAMMENSEE
  • Publication number: 20210340217
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: June 17, 2021
    Publication date: November 4, 2021
    Inventors: Heiko SCHUSTER, Janet PEPER, Kevin ROEHLE, Philipp WAGNER, Hans-Georg RAMMENSEE
  • Publication number: 20210340216
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: June 17, 2021
    Publication date: November 4, 2021
    Inventors: Heiko SCHUSTER, Janet PEPER, Kevin ROEHLE, Philipp WAGNER, Hans-Georg RAMMENSEE
  • Patent number: 11154020
    Abstract: In various embodiments, an apparatus for growing plants is provided. The apparatus may include an irrigation apparatus, an accommodating space for accommodating one or more seed mats, and a controller which is configured to control the irrigation apparatus by a program controller. The irrigation apparatus includes a water circuit system for feeding water to the seed mats. The water circuit system includes at least one inlet, a water tank, at least one water circuit pump and at least one outlet. The irrigation apparatus includes a sensor which is configured to determine a conductance of the fed water.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: October 26, 2021
    Assignee: AGRILUTION SYSTEMS GMBH
    Inventors: Maximilian Loessl, Philipp Wagner
  • Patent number: 11130399
    Abstract: A multi-clutch device for a hybrid module includes a separating clutch, a dual clutch device, a first pivot bearing, a common rotary part, a second pivot bearing, a gear element, and a clamping device. The separating clutch is for transmitting torque from an internal combustion engine to the multi-clutch device. The dual-clutch device is for transmitting torque to a drivetrain. The dual clutch device includes a first partial clutch and a second partial clutch. The common rotary part is mounted rotatably by the first pivot bearing, and couples the separating clutch, the first partial clutch, and the second partial clutch in a rotationally fixed manner. The gear element is mounted rotatably by the second pivot bearing, and forms a gear between the electrical machine and the multi-clutch device. The clamping device is for clamping the common rotary part and the gear element against each other in the axial direction.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: September 28, 2021
    Assignee: Schaeffler Technologies AG & Co. KG
    Inventors: Simon Ortmann, Patrick Oberle, Philippe Wagner, Manuel Bassler
  • Publication number: 20210260122
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: April 30, 2021
    Publication date: August 26, 2021
    Inventors: Heiko SCHUSTER, Janet PEPER, Philipp WAGNER, Hans-Georg RAMMENSEE
  • Publication number: 20210260123
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: April 30, 2021
    Publication date: August 26, 2021
    Inventors: Heiko SCHUSTER, Janet PEPER, Philipp WAGNER, Hans-Georg RAMMENSEE
  • Publication number: 20210252066
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: April 30, 2021
    Publication date: August 19, 2021
    Inventors: Heiko SCHUSTER, Janet PEPER, Philipp WAGNER, Hans-Georg RAMMENSEE
  • Publication number: 20210252065
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: April 30, 2021
    Publication date: August 19, 2021
    Inventors: Heiko SCHUSTER, Janet PEPER, Philipp WAGNER, Hans-Georg RAMMENSEE
  • Publication number: 20210252064
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: April 30, 2021
    Publication date: August 19, 2021
    Inventors: Heiko SCHUSTER, Janet PEPER, Philipp WAGNER, Hans-Georg RAMMENSEE
  • Patent number: 11078253
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: August 3, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Heiko Schuster, Janet Peper, Kevin Roehle, Philipp Wagner, Hans-Georg Rammensee
  • Publication number: 20210229544
    Abstract: A multi-clutch device for a hybrid module includes a separating clutch, a dual clutch device, a first pivot bearing, a common rotary part, a second pivot bearing, a gear element, and a clamping device. The separating clutch is for transmitting torque from an internal combustion engine to the multi-clutch device. The dual-clutch device is for transmitting torque to a drivetrain. The dual clutch device includes a first partial clutch and a second partial clutch. The common rotary part is mounted rotatably by the first pivot bearing, and couples the separating clutch, the first partial clutch, and the second partial clutch in a rotationally fixed manner. The gear element is mounted rotatably by the second pivot bearing, and forms a gear between the electrical machine and the multi-clutch device. The clamping device is for clamping the common rotary part and the gear element against each other in the axial direction.
    Type: Application
    Filed: April 18, 2019
    Publication date: July 29, 2021
    Applicant: Schaeffler Technologies AG & Co. KG
    Inventors: Simon Ortmann, Patrick Oberle, Philippe Wagner, Manuel Bassler
  • Patent number: 11071756
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: December 9, 2020
    Date of Patent: July 27, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Heiko Schuster, Janet Peper, Philipp Wagner, Hans-Georg Rammensee
  • Patent number: 11064659
    Abstract: A device for cultivating plants is provided, comprising a watering device, an illuminating device, one or more seed mats, and a control unit configured to control the watering device and the illuminating device by means of a program controller, wherein the program controller comprises watering data and illuminating data which is individually matched to the one or more seed mats.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: July 20, 2021
    Assignee: Agrilution Systems GmbH
    Inventors: Maximilian Loessl, Philipp Wagner
  • Patent number: 11058070
    Abstract: In various embodiments, an apparatus for growing plants is provided. The apparatus may include an irrigation apparatus, an illumination apparatus, a climate control device, an accommodating space for accommodating one or more seed mats, a controller which is configured to control the irrigation apparatus, the illumination apparatus and the climate control apparatus by means of a program controller, at least one air humidity sensor for determining an air humidity in the accommodating space, and at least one temperature sensor for determining an air temperature in the accommodating space.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: July 13, 2021
    Assignee: Agrilution Systems GmbH
    Inventors: Maximilian Loessl, Philipp Wagner
  • Patent number: 11053296
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: July 6, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Heiko Schuster, Janet Peper, Kevin Roehle, Philipp Wagner, Hans-Georg Rammensee
  • Publication number: 20210106624
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: December 16, 2020
    Publication date: April 15, 2021
    Inventors: Heiko SCHUSTER, Janet PEPER, Philipp WAGNER, Hans-Georg RAMMENSEE
  • Publication number: 20210106623
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: December 9, 2020
    Publication date: April 15, 2021
    Inventors: Heiko SCHUSTER, Janet PEPER, Philipp WAGNER, Hans-Georg RAMMENSEE